The results described above provided the basis for studies evaluating how Rictor and/or EGFR silencing influence GBM cell migration in vitro and exploring whether silencing of these targets influenced cell sensitivity to conventional agents known to exert activity in patients with GBM. Here, EGFR is linked to glioblastoma.